Universidade Federal De Minas Gerais

Universidade Federal De Minas Gerais - Ufmg

Erna Geessien Kroon

Paulo C P Ferreira

Jenner Karlisson Pimenta Dos Reis

Paulo Cesar Peregrino Ferreira

Isabella Bias Fortes Ferraz

Rômulo Cerqueira Leite

Romulo C Leite

Isabella B F Ferraz

Paulo C&eacute;sar Peregrino Ferreira

Jenner K P Dos Reis

Flavio G Da Fonseca

R&ocirc;mulo Cerqueira Leite

Romain Rolland Golgher

Paulo César Peregrino Ferreira

Alex Fiorini De Carvalho

Claudio Antonio Bonjardim

The present invention relates to a method and kit for detecting antibodies in clinical samples of animals infected with equine infectious anemia virus using the immunodiagnosis with the recombinant viral antigen p26. The antigen was bound to solid supports (microtitter plates, tubes, beads or nitrocellulose papers or nylon) and reacted with the test serum. After incubation with conjugated anti-equine immunoglobulin-enzyme the reaction was revealed with a solution composed of the substrate of the enzyme used in the conjugate (cromogene). After development of the reaction (color formation) it was stopped with acid solution and measured. The immunoassay may be a direct second antibody immunoassay, a one or two step sandwich immunoassay.

Method and composition for the diagnosis of equine infectious anemia virus disease by using the recombinant capsid protein virus (p26)

The present invention describes recombinant p24/p17 hybrid protein derived from the human immunodeficiency virus, their corresponding encoding recombinant DNA molecule and the process of production of the recombinant protein produced through genetic engineering techniques, to be used in diagnosis, vaccination or in research.

Process for expression and production of recombinant protein hybrid protein (p24/p17) derived from human immunodeficiency viruses (HIV-1)

The present invention describes recombinant gp90 envelop protein derived from the equine infectious anemia virus, their corresponding encoding recombinant DNA molecule and the process of production of the recombinant protein produced through genetic engineering techniques, to be used in diagnosis, vaccination or in research.

Method of producing a recombinant non-glycosylated gp90 of equine infectious anemia virus (EIAV), and product thereof

The present invention describes recombinant growth factor (BEGF) protein isolated from the virus BeAn58058, their corresponding encoding recombinant DNA molecule and the process of production of the recombinant BEGF protein produced through genetic engineering techniques, to be used in human or veterinarian clinical or in research.

Process for the expression and production of the recombinant growth factor protein (BEGF) derived from BEAN 58058 virus (BEV)

The invention provides a new human interferon (IFN)-&bgr; variant cloned from an amniotic cell library, a cDNA encoding it, and processes for its production and purification. The variant, termed interferon beta-cis, differs from previously known hIFN-&bgr; isoforms by the substitution of a Cys residue for the Tyr present at position 60. Recombinant IFN beta-cis exhibits antiviral activity characteristic of IFN-&bgr;.

Recombinant human beta-CIS interferon

Growing community of inventors

Belo Horizonte, Brazil

Erna Geessien Kroon